Personalized cell therapy tested for Hard-to-Treat scleroderma
NCT ID NCT06400303
Summary
This early-stage study is testing a new personalized cell therapy called KYV-101 for adults with active, diffuse systemic sclerosis (scleroderma). The therapy involves modifying a patient's own immune cells to target and remove certain B-cells thought to drive the disease. The main goals are to check the treatment's safety and see if it can improve disease activity and symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwell Health
Great Neck, New York, 11021, United States
-
Stanford University Medical Center
Palo Alto, California, 94305, United States
Conditions
Explore the condition pages connected to this study.